Approximately 1/12 Canadians are affected by a rare disease and prompt diagnosis is imperative as symptom management, and treatment options can drastically improve quality of life. Share the message of awareness and find what makes you rare. Maclean’s Photo Credit: Patrick Chondon http://www.macleans.ca/sponsored/from-pain-to-empowerment-with-fabry-disease/
Exciting news for the CFA Community – Replagal has been approved by Health Canada as of February 2017 and all patients have been transitioned from the REP-081 study at this point. Replagal is a long-term Enzyme Replacement Therapy (ERT), the infusion will be given every 2 weeks, treatment time being approximately 4o minutes. It is […]
In the 16-week clinical trials expected to start later this year — if the research method is given the nod by the QE II’s ethics committee — the researchers led by West and Khan will measure the effects of the drug apabetalone on 44 patients suffering with Fabry disease.
Subscribe error, please review your email address.Close
You're now subscribed, thank you!Close
There was a problem with your submission. Please check the field(s) with red label below.Close
Your message has been sent. We'll get back to you soon!Close